Gilead sciences Study guides, Class notes & Summaries

Gilead Sciences and Sovaldi: The Cost of a Cure (A) Introduction December 6, 2013, had the makings of a good day for Gilead Sciences, Inc. The United States Food and Drug Administration (FDA) had just approved Sovaldi,1 a hepatitis C treatment, after a wildly successful trial program that saw more than 90% of patients cured.2 In addition, the cost of the treatment would be in line with less effective hepatitis C treatments, and several times lower than the cost of treating or replacin...